Taking these first steps will help you determine if entrepreneurship is a good fit. Graphic by Miguel Tovar/University of Houston

If you are a faculty inventor, you’re likely also interested in becoming a faculty entrepreneur. Aspiring to be an entrepreneur is the first step, but what should you do next?

Take action

Bruce Fischer, professor of business and economics at Elmhurst University, said in a blog post that “above all, you should take action” and not procrastinate.

Fischer suggests taking a course in entrepreneurship that covers the fundamentals of management.

Your university is a great place to start. For instance, the University of Houston houses the Gulf Coast chapter of the Small Business Development Center, which offers in-person and online trainings as well as free business advising.

The Bauer School of Business at UH also has programming suited to entrepreneurs at various stages of experience. Depending on where you live corporate, nonprofit, and government-sponsored startup development organizations may also provide resources to introduce you to the fundamentals of entrepreneurship.

Find a mentor

Fischer also stresses the importance of finding a mentor. Find someone, maybe someone you know, that is already in the entrepreneurial space. Maybe they already have their own business, and they can give you help on your entrepreneurial journey.

The Associate Director of Startup Development at UH, Tanushree Chatterji, offered some advice for first time entrepreneurs.

“Networking is the key. Going to every relevant event and introducing yourself and talking about what you are doing is the most effective way to network. There are a lot of folks looking to mentor, you have to find them,” she said.

One way to get the conversation going is to reach out to your university’s office of technology transfer.

What's the big idea?

If you are a creative and passionate person, then maybe entrepreneurship is right for you. Taking these first steps will help you determine if entrepreneurship is a good fit while giving you exposure to the fundamentals of establishing your own business.

Fischer leaves us with some parting words of encouragement: “Don’t be afraid to ask for help. Entrepreneurs are a close community because they can relate to one another through their shared experiences.”

------

This article originally appeared on the University of Houston's The Big Idea. Cory Thaxton, the author of this piece, is the communications coordinator for The Division of Research.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”